Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells.

By Pravin J. Mishra, P. Mishra, R. Humeniuk, D. Medina, G. Alexe, Jill P. Mesirov, Sridharan Ganesan, J. Glod, D. Banerjee. Cancer Research, 2008

834 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model (2013, methodology): “MSCs were passaged and identified by surface marker analysis and in vitro differentiation assays [15].”
Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs (2019, background): “Human bone marrow-derived MSCs (BM-MSCs) were shown to adopt a CAF-like phenotype with similar functional properties after prolonged exposure to tumorconditioned medium (100, 101).”
Fibroblast heterogeneity in the cancer wound (2014, background): “In addition to these local sources of CAFs, bone marrow–derived cells termed fibrocytes can be recruited to the tumor and differentiate into myofibroblasts and fibroblasts (Ishii et al., 2003; Direkze et al., 2004; Mishra et al., 2008; Kidd et al., 2012).”
Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts (2010, neutral): “Smad4-shRNA2 5′-AGGTGTGCAGTTGGAATGTAA-3′ (15) p53-shRNA 5′-GACTCCAGTGGTAATCTAC-3′ (16)”
Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth (2011, positive): “Previous studies have suggested that MSCs can be induced to differentiate into CAFs, particularly when exposed to tumorconditioned media (Mishra et al., 2008).”